Molecular mechanisms for bone marrow failure and clonal progression during the innate immune response in Fanconi Anemia
范可尼贫血先天免疫反应期间骨髓衰竭和克隆进展的分子机制
基本信息
- 批准号:10348140
- 负责人:
- 金额:$ 35.57万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-04-01 至 2024-01-31
- 项目状态:已结题
- 来源:
- 关键词:ATR checkpointAdjuvantAdverse effectsAnemiaAntigensApoptosisBone MarrowBone Marrow CellsBone Marrow Stem Cell TransplantationBone marrow failureCD34 geneCSF3 geneCandidaCell CycleCell Cycle ArrestCell Cycle CheckpointCellsCessation of lifeChildhoodChronicClonal ExpansionComplementComplicationCongenital DisordersDNADNA DamageDNA RepairDNA Repair PathwayDNA replication forkDiseaseDysplasiaEmergency SituationErythroidEventFanconi&aposs AnemiaFunctional disorderGene ExpressionGenesGenetic ModelsGenetic TranscriptionGenotoxic StressGoalsGranulopoiesisHematopoiesisHematopoieticHereditary DiseaseHumanInfectionInflammationInheritedInjectionsInnate Immune ResponseInterleukin-1Interleukin-1 betaInterruptionLeadMediatingMolecularMorbidity - disease rateMusMutagenesisMutationMyelogenousMyeloid LeukemiaNADPH OxidasePancytopeniaPathway interactionsPatientsPhagocytesProcessProductionReactive Oxygen SpeciesRecurrenceRegulatory PathwayResistanceRoleS phaseSignal TransductionStimulusStressSurvivorsTP53 geneTestingTherapeuticWild Type Mouseadverse outcomealuminum sulfateantagonistcrosslinkcytokinedensitygranulocytegranulocyte-monocyte progenitorshematopoietic stem cell expansionleukemiamortalitymouse modelnovelpathogenpreclinical studypreventprogenitorrepairedresponsescreeningsmall molecule inhibitorstemstem cellstranscription factortranslational potential
项目摘要
The Fanconi DNA repair pathway is required for rescue of stalled or collapsed replication forks. Fanconi
Anemia (FA) is caused by inherited mutation of Fanconi genes. FA patients develop bone marrow failure (BMF)
in childhood, with survivors frequently developing clonal progression. We identified a role for emergency (stress)
granulopoiesis (EG) in BMF and clonal progression in FA. EG is an episodic process for granulocyte production
in response to infectious challenge. During EG, S phase is shortened and FancC and F expression increase.
Unlike wild type mice, Fancc-/- mice did not develop granulocytosis upon stimulation of EG. Repeated EG
challenge in Fancc-/- mice induced either BMF, with apoptosis of HSC and progenitors, or clonal progression.
Treatment of Fancc-/- mice with an IL1-R antagonist protected them from these adverse consequences. IL1β is
an essential cytokine for EG; inducing myeloid lineage commitment, and G-CSF expression. During the S phase,
Atr activates p53 and apoptosis of cells with unrepaired replication fork damage. In Fancc-/- mice, Tp53-haplo-
insufficiency rescued granulocytosis during EG; delaying BMF but accelerating clonal progression. In Fancc-/-
mice, increasing activity of Atr/p53 occurred with each unsuccessful EG episode; associated with BMF. In
contrast, Atr/p53 activity decreased with consecutive, successful EG cycles in Fancc-/-Tp53+/- mice.
We hypothesize unsuccessful PMN production in FA during EG prevents activation of unknown negative
regulatory pathways; sustaining cell cycle checkpoint activity and HSC/GMP expansion signals. This induces
BMF and accumulation of mutations that lead to clonal progression. We will pursue this through three aims:
Aim 1: Define molecular triggers for termination of emergency granulopoiesis and the role of this
process in BMF in FA. We will investigate contribution of PMN density to apoptosis and BMF during
unsuccessful EG in Fancc-/- mice. The impact of PMN bone marrow density on known EG-related pathways will
be determined in Wt vs Fancc-/- mice, and novel pathways identified in non-biased studies.
Aim 2: Identify events associated with emergency granulopoiesis-induced clonal progression in FA.
We will define events involved in clonal progression in Fancc-/- mice by studying leukemia suppressor pathways
that mediate EG termination and by non-biased approaches. Results will be compared to gene expression
profiles in CD34+ bone marrow cells from human Fanconi Anemia to identify potential translational targets.
Aim 3: Investigate potential translational targets to delay BMF or clonal progression in FA. We will
determine the impact of novel pathways that are activated during EG on BMF and/or clonal progression in murine
genetic models. Relevant intermediates with small molecule inhibitors will be tested in pre-clinical studies.
The goal of these studies is to define molecular mechanisms for BMF and/or clonal progression during
recurrent, unsuccessful EG attempts in FA. This may suggest therapeutic approaches to decrease morbidity due
to anemia and infection, or bridge patients to definitive treatments such as stem cell/bone marrow transplant.
Fanconi DNA 修复途径是挽救停滞或崩溃的复制叉所必需的。
贫血 (FA) 是由 Fanconi 基因遗传性突变引起的 FA 患者会出现骨髓衰竭 (BMF)。
在童年时期,幸存者经常出现克隆进展,我们确定了紧急情况(压力)的作用。
BMF 中的粒细胞生成 (EG) 和 FA 中的克隆进展是粒细胞生成的一个间歇性过程。
在 EG 期间,S 期缩短,FancC 和 F 表达增加。
与野生型小鼠不同,Fancc-/-小鼠在重复EG刺激后不会出现粒细胞增多症。
Fancc-/- 小鼠中的攻击诱导 BMF(伴随 HSC 和祖细胞凋亡)或克隆进展。
用 IL1-R 拮抗剂治疗 Fancc-/- 小鼠可以保护它们免受这些不良后果的影响。
EG 的重要细胞因子;诱导骨髓谱系定型和 S 期 G-CSF 表达。
Atr 激活 Fancc-/- 小鼠中复制叉损伤未修复的 p53 和细胞凋亡,Tp53-haplo-。
EG 期间的不足挽救了粒细胞增多;延迟了 BMF,但加速了 Fancc-/- 的克隆进展。
在小鼠中,每次不成功的 EG 发作都会增加与 BMF 相关的 Atr/p53 活性。
相比之下,Fancc-/-Tp53+/- 小鼠中 Atr/p53 活性随着连续、成功的 EG 周期而降低。
我们在 EG 期间未能成功地在 FA 中生产 PMN,以防止未知阴性的激活
调节途径;维持细胞周期检查点活性和 HSC/GMP 扩展信号。
BMF 和导致克隆进展的突变积累我们将通过三个目标来实现这一目标:
目标 1:定义终止紧急粒细胞生成的分子触发因素及其作用
我们将研究 FA 过程中 PMN 密度对细胞凋亡和 BMF 的贡献。
Fancc-/- 小鼠中的 EG 不成功 PMN 骨髓密度对已知 EG 相关途径的影响将。
在 Wt 与 Fancc-/- 小鼠中确定,并且在无偏见研究中确定了新的途径。
目标 2:确定 FA 中与紧急粒细胞生成诱导的克隆进展相关的事件。
我们将通过研究白血病抑制途径来定义 Fancc-/- 小鼠克隆进展中涉及的事件
介导 EG 终止并通过无偏见方法将结果与基因表达进行比较。
来自人类范可尼贫血的 CD34+ 骨髓细胞的分析,以确定潜在的转化靶标。
目标 3:研究延迟 BMF 或 FA 克隆进展的潜在转化靶点。
确定 EG 期间激活的新途径对小鼠 BMF 和/或克隆进展的影响
相关的小分子抑制剂中间体将在临床前研究中进行测试。
这些研究的目标是确定 BMF 和/或克隆进展的分子机制。
在 FA 中反复进行 EG 尝试但不成功,这可能表明可以采取治疗方法来降低发病率。
贫血和感染,或为患者提供明确的治疗,例如干细胞/骨髓移植。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Elizabeth Ann Eklund其他文献
Elizabeth Ann Eklund的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Elizabeth Ann Eklund', 18)}}的其他基金
Molecular mechanisms of drug resistance and disease progression in acute myeloid leukemia.
急性髓系白血病耐药和疾病进展的分子机制。
- 批准号:
10698907 - 财政年份:2019
- 资助金额:
$ 35.57万 - 项目类别:
Molecular mechanisms of drug resistance and disease progression in acute myeloid leukemia
急性髓系白血病耐药和疾病进展的分子机制
- 批准号:
9922661 - 财政年份:2019
- 资助金额:
$ 35.57万 - 项目类别:
Identifying molecular markers that predict relapse after therapy discontinuation inchronic myeloid leukemia.
识别预测慢性粒细胞白血病治疗停止后复发的分子标记。
- 批准号:
9922662 - 财政年份:2019
- 资助金额:
$ 35.57万 - 项目类别:
Identifying molecular markers that predict relapse after therapy discontinuation inchronic myeloid leukemia.
识别预测慢性粒细胞白血病治疗停止后复发的分子标记。
- 批准号:
10427231 - 财政年份:2019
- 资助金额:
$ 35.57万 - 项目类别:
Molecular mechanisms of drug resistance and disease progression in acute myeloid leukemia
急性髓系白血病耐药和疾病进展的分子机制
- 批准号:
10265363 - 财政年份:2019
- 资助金额:
$ 35.57万 - 项目类别:
Identifying molecular markers that predict relapse after therapy discontinuation inchronic myeloid leukemia.
识别预测慢性粒细胞白血病治疗停止后复发的分子标记。
- 批准号:
10291794 - 财政年份:2019
- 资助金额:
$ 35.57万 - 项目类别:
Molecular mechanisms of drug resistance and disease progression in acute myeloid leukemia
急性髓系白血病耐药和疾病进展的分子机制
- 批准号:
10454870 - 财政年份:2019
- 资助金额:
$ 35.57万 - 项目类别:
Molecular mechanisms for bone marrow failure and clonal progression during the innate immune response in Fanconi Anemia
范可尼贫血先天免疫反应期间骨髓衰竭和克隆进展的分子机制
- 批准号:
9895782 - 财政年份:2019
- 资助金额:
$ 35.57万 - 项目类别:
Triad1 regulates myelopoiesis and functions as a leukemia suppressor
Triad1 调节骨髓细胞生成并发挥白血病抑制因子的作用
- 批准号:
8891685 - 财政年份:2015
- 资助金额:
$ 35.57万 - 项目类别:
Triad1 regulates myelopoiesis and functions as a leukemia suppressor
Triad1 调节骨髓细胞生成并发挥白血病抑制因子的作用
- 批准号:
9032480 - 财政年份:2015
- 资助金额:
$ 35.57万 - 项目类别:
相似国自然基金
肿瘤微环境多层次调控的功能化纳米佐剂用于增强膀胱癌放疗疗效的机制研究
- 批准号:82303571
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
靶向FPPS的双磷酸疫苗佐剂的开发
- 批准号:82341040
- 批准年份:2023
- 资助金额:100 万元
- 项目类别:专项基金项目
皮内接种抗原佐剂复合疫苗跨器官诱导呼吸道黏膜免疫反应
- 批准号:82341042
- 批准年份:2023
- 资助金额:100 万元
- 项目类别:专项基金项目
双重生物响应性自佐剂聚多肽载体构建高效mRNA癌症疫苗
- 批准号:52373299
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
新型免疫调节复合佐剂的机制研究及在疫苗开发中的应用
- 批准号:82341039
- 批准年份:2023
- 资助金额:95 万元
- 项目类别:专项基金项目
相似海外基金
Immunomodulatory biomaterial to enhancing T-cell responses to triple negative breast cancer
免疫调节生物材料可增强 T 细胞对三阴性乳腺癌的反应
- 批准号:
10699815 - 财政年份:2023
- 资助金额:
$ 35.57万 - 项目类别:
Develop Conditionally Armored CAR Macrophage Therapy for Pancreatic Cancer
开发针对胰腺癌的条件装甲 CAR 巨噬细胞疗法
- 批准号:
10710883 - 财政年份:2023
- 资助金额:
$ 35.57万 - 项目类别:
Validation of the joint-homing and drug delivery attributes of novel peptides in a mouse arthritis model
在小鼠关节炎模型中验证新型肽的关节归巢和药物递送特性
- 批准号:
10589192 - 财政年份:2023
- 资助金额:
$ 35.57万 - 项目类别:
Targeting the HMGB1-TLR5 pathway to prevent senescence-induced metastasis in breast cancer.
靶向 HMGB1-TLR5 通路预防乳腺癌衰老诱导的转移。
- 批准号:
10599637 - 财政年份:2023
- 资助金额:
$ 35.57万 - 项目类别:
Development of contrast agents to facilitate image-guided surgery
开发造影剂以促进图像引导手术
- 批准号:
10810184 - 财政年份:2023
- 资助金额:
$ 35.57万 - 项目类别: